期刊
CHEMBIOCHEM
卷 22, 期 12, 页码 2124-2133出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbic.202100016
关键词
antimicrobial; biofilms; innate immunity; lactoferrin; Streptococcus
资金
- National Institutes of Health [R01 HD090061]
- National Science Foundation [1547757, 1400969]
- March of Dimes
- Vanderbilt Institute for Clinical and Translational Research program - National Center for Research Resources [UL1 RR024975-01]
- National Center for Advancing Translational Sciences [2 UL1 TR000445-06]
- NIH [T32HL007411-36S1, 2T32AI112541-06, K08AI151100, R35GM133602, F32HD100087, U01TR002398, R01AI134036]
- Direct For Education and Human Resources
- Division Of Human Resource Development [1400969] Funding Source: National Science Foundation
Group B Streptococcus (GBS) is a pathogen that causes invasive infections in pregnant hosts, neonates, and immunocompromised individuals, while human breast milk lactoferrin has antimicrobial and anti-biofilm activity against GBS.
Group B Streptococcus (GBS) is an encapsulated Gram-positive human pathogen that causes invasive infections in pregnant hosts and neonates, as well as immunocompromised individuals. Colonization of the human host requires the ability to adhere to mucosal surfaces and circumnavigate the nutritional challenges and antimicrobial defenses associated with the innate immune response. Biofilm formation is a critical process to facilitate GBS survival and establishment of a replicative niche in the vertebrate host. Previous work has shown that the host responds to GBS infection by producing the innate antimicrobial glycoprotein lactoferrin, which has been implicated in repressing bacterial growth and biofilm formation. Additionally, lactoferrin is highly abundant in human breast milk and could serve a protective role against invasive microbial pathogens. This study demonstrates that human breast milk lactoferrin has antimicrobial and anti-biofilm activity against GBS and inhibits its adherence to human gestational membranes. Together, these results indicate that human milk lactoferrin could be used as a prebiotic chemotherapeutic strategy to limit the impact of bacterial adherence and biofilm formation on GBS-associated disease outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据